US government agencies have questioned the legality of cannabidiol (CBD) – just as the industry is starting to see the benefits of increased public awareness.
Actions by both the US Food and Drug Administration (FDA) and the US Drug Enforcement Administration (DEA) have recently cast doubt on the future of CBD, according to speakers at the Marijuana Business Conference (MJBizCon) held May 9th–11th in New Orleans.
The situation is further complicated by the lack of clarity over the status of CBD, as some stakeholders classify it as a drug and others as a dietary supplement. Speakers at the conference also discussed a potential loophole that would allow CBD to be legally sold as a product derived from industrial hemp.
Restricted content. Do you want to read more?
Sign up NOW for 7 days FREE TRIAL and access our briefings section
CBD as a Novel Food: the future for edibles in Europe
Avoid the risks of online misinformation. This report, from our sister platform CBD-Intel, provides an exclusive in-depth analysis with practical information for your business. All you need to know about CBD and Novel Foods in one place!
Do you want to understand the industry impact of Novel Food regulations and future scenarios? Then you cannot miss our new report.
This report also includes a 1-hour consultation call with CBD-Intel’s analyst team.